TARDBP and amyotrophic lateral sclerosis: As with FTLD, many studies have explored the mechanisms whereby TDP-43 influences ALS pathogenesis, but at present these studies have been inconclusive and have yielded inconsistent results, suggesting more work is needed to establish the therapeutic value of targeting TDP-43 in this disease.